The phase 1b, KEYNOTE-028 [15] trial evaluated safety and efficacy of pembrolizumab in 25 patients with PDL-1-positive recurrent glioblastoma and 31% of patients had already received two or more lines of chemotherapy. This evidence concerns the gene CD274 and glioblastoma.